EU regulator backs use of Wegovy for obesity-related heart disease

The European Medicines Agency has backed the use of Novo Nordisk’s vaccine, the popular drug Wegovy, to help relieve heart failure in people with obesity, the Danish drugmaker announced.

Teile diesen Beitrag: